1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014

Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 54 pages

Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014’, provides an overview of the Paraganglioma (Glomus Jugulare Tumor)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Paraganglioma (Glomus Jugulare Tumor), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paraganglioma (Glomus Jugulare Tumor) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Paraganglioma (Glomus Jugulare Tumor)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Paraganglioma (Glomus Jugulare Tumor) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Paraganglioma (Glomus Jugulare Tumor) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Paraganglioma (Glomus Jugulare Tumor) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Paraganglioma (Glomus Jugulare Tumor)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Paraganglioma (Glomus Jugulare Tumor) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Paraganglioma (Glomus Jugulare Tumor) - Pipeline Review, H2 2014
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Paraganglioma (Glomus Jugulare Tumor) Overview 6
Therapeutics Development 7
Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) - Overview 7
Pipeline Products for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis 8
Paraganglioma (Glomus Jugulare Tumor) - Therapeutics under Development by Companies 9
Paraganglioma (Glomus Jugulare Tumor) - Pipeline Products Glance 10
Clinical Stage Products 10
Paraganglioma (Glomus Jugulare Tumor) - Products under Development by Companies 11
Paraganglioma (Glomus Jugulare Tumor) - Companies Involved in Therapeutics Development 12
AstraZeneca PLC 12
Novartis AG 13
Pfizer Inc. 14
Progenics Pharmaceuticals, Inc. 15
Paraganglioma (Glomus Jugulare Tumor) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 24
dovitinib lactate - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
everolimus - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
iobenguane sulfate I 131 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
sunitinib malate - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
vandetanib - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Paraganglioma (Glomus Jugulare Tumor) - Recent Pipeline Updates 45
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54

List of Tables

Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2014 7
Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Products under Development by Companies, H2 2014 11
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by AstraZeneca PLC, H2 2014 12
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Novartis AG, H2 2014 13
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Pfizer Inc., H2 2014 14
Paraganglioma (Glomus Jugulare Tumor) - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 15
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Stage and Target, H2 2014 18
Number of Products by Stage and Mechanism of Action, H2 2014 20
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 23
Paraganglioma (Glomus Jugulare Tumor) Therapeutics - Recent Pipeline Updates, H2 2014 45

List of Figures

Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor), H2 2014 7
Number of Products under Development for Paraganglioma (Glomus Jugulare Tumor) - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Assessment by Monotherapy Products, H2 2014 16
Number of Products by Top 10 Targets, H2 2014 17
Number of Products by Stage and Top 10 Targets, H2 2014 17
Number of Products by Top 10 Mechanism of Actions, H2 2014 19
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 19
Number of Products by Top 10 Routes of Administration, H2 2014 21
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 22
Number of Products by Stage and Top 10 Molecule Types, H2 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.